Single-Dose Of Covaxin On Covid-Recovered People Gives Similar Response As Two Doses On Uninfected: ICMR StudyBharat Biotech's COVAXIN (Representative Image) (Pic Via BBIL Website)

One of the pilot studies conducted by the Indian Council of Medical Research (ICMR) shows that a single dose of Covaxin on people recovered from Covid-19 is as effective as two doses administered to uninfected individuals.

ICMR has asserted that these are only preliminary findings and that it needs to be corroborated with larger units of data.

Moreover, the authors of the research maintain that taking both doses of the vaccine developed by Bharat Biotech is still recommended.

This study conducted by the ICMR involved frontline and healthcare workers that were examined for e SARS-CoV-2–specific antibody responses after day zero (baseline, before vaccination), Day 28 (month 1) and Day 56 post-first dose (month 2) of Covaxin.

“This study offers evidence in support of public health-oriented and immunologically sustained vaccine strategies,” the study published by ICMR reads, as reported by the Economic Times.

It added, “If our preliminary findings are confirmed in large population studies, a single dose of BBV152 vaccine may be recommended to previously confirmed SARS-CoV-2 infected individuals so that the naïve individuals could attain the larger benefit of a limited vaccine supply.”

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber
Advertisement